- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02412553
Terapia dietetica e microbioma intestinale nella malattia di Crohn e nella colite ulcerosa
The study is proposed as a 2-year single site, open-label clinical trial of enteral nutrition or the specific carbohydrate diet in patients with active CD or UC. Patients seeking care in the outpatient clinics of the Division of Gastroenterology at Massachusetts General Hospital will be approached for participation in the trial during their routine outpatient appointments. All patients are required to have a diagnosis of CD or UC confirmed using standard clinical, endoscopic, and histologic criteria. Eligible patients will complete an office visit to confirm eligibility for the study and informed consent will be obtained. They will then be scheduled for a routine colonoscopy as part of their standard clinical care to objectively confirm active disease and obtain biopsies for microbiome and gene expression. The investigators will obtain prior authorization from the subject's insurance company for such colonoscopy, or if it is not covered by the insurance, the investigators will use study funds to pay for the procedure. They will then be assigned to one of two dietary intervention arms based on their preference and will meet with the study registered dietician at the MGH Clinical Research Center (CRC) metabolism and nutrition unit. There, they will receive instruction on the components of the assigned dietary therapy arm - partial elemental diet (enteral nutrition) or specific carbohydrate diet, and will complete a baseline food record (FR). They will adhere to the dietary therapy for 6 weeks after which they can resume normal diet. Clinical, biochemical, nutritional, and microbiological parameters will be measured during and for 6 weeks following the study. They will have 5 study visits during this time.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- At least 18 years of age
- Able to provide written informed consent prior to screening and to comply with the requirements of the study protocol.
- Established diagnosis of small bowel or colonic CD or ulcerative colitis
- Confirmation of active CD or UC with recent (within 1 month) objective evidence of active disease on colonoscopy
- Any medications being currently used for IBD must remain stable during the study period with the exception of tapering of corticosteroids.
- Current disease activity defined as a Harvey Bradshaw index > 4 at baseline (week 0) or SCCAI > 3
Exclusion Criteria:
- If female, is pregnant or is breast feeding
- Known celiac disease or subjects with a positive screen for celiac disease (elevated tissue transglutaminase antibodies)
- Inability to provide informed consent or unwilling to participate
- Evidence of untreated infection e.g. clostridium difficile
- Presence of stoma or J pouch
- Presence of enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period
- Bowel surgery within 12 weeks prior to screen and/or has surgery planned or deemed likely for IBD during the study period
- Fixed symptomatic stenosis of small bowel or colon
- Chronic use of narcotics for chronic pain defined as a daily use of one or more doses of narcotic containing medication
- Use of oral or intravenous antibiotics within 4 weeks prior to screening
- Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Specific carbohydrate arm
The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient. |
|
|
Comparatore attivo: Elemental diet arm
The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical remission
Lasso di tempo: Week 6
|
Harvey Bradshaw index < 4 or SCCAI < 3 at week 6 |
Week 6
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical response
Lasso di tempo: Week 6
|
reduction in HBI by 3 or more or SCCAI by 2 or more |
Week 6
|
|
Biochemical response - CRP
Lasso di tempo: Week 6
|
Change in serum C-reactive protein from baseline |
Week 6
|
|
Biochemical response - fecal calprotectin
Lasso di tempo: Week 6
|
Change in fecal calprotectin from baseline |
Week 6
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in gut microbiome
Lasso di tempo: Week 6 and Week 12
|
Change in fecal microbiome pattern assessed using 16sRNA sequencing and shotgun metagenomic sequencing |
Week 6 and Week 12
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2014P001134
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .